SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSosandar Regulatory News (SOS)

Share Price Information for Sosandar (SOS)

Share Price is delayed by 15 minutes
Get Live Data
11.00    0.00 (0.00%)
Bid:
10.50
Ask:
11.50
Spread: 1.00 (9.524%)
Market Cap: £24.00m
SOS Live PriceLast checked at - London Stock Exchange

Intraday Sosandar Share Chart

Half Yearly Report

18 Dec 2009 09:21

RNS Number : 3642E
Medavinci PLC
18 December 2009
 



For Immediate Release

18 December 2009

MeDaVinci plc

("MDV" or "the Company" or "the Group")

Interim Results 

CHAIRMAN'S STATEMENT

As highlighted in the Chairman's Statement in the financial accounts for the year ended 31 March 2009, there have been a number of recent changes in the Company. In particular, myself and Paul Foulger have taken executive control of the Company and are making good progress in restructuring a business which had been left in a poor financial and commercial state by the previous executive board.

Key highlights are:

On 8 July 2009, we concluded a rescue fundraising which brought a much needed £421,540 of funds into the Company. Some of this money was used to pay off old creditors albeit the large majority of it is for working capital purposes, enabling the Company to further develop its activities.

In September 2009, we set up a new subsidiary, Emotion Fitness Ltd, and then effected the transfer of MeDaVinci plc's 49% stake in the Hungarian based Emotion Fitness business into the new subsidiary from MeDaVinci Healthcare Services B.V.

We are now finalising our review of the Company's previous investments (DemecalErgoDynamics, and Emotion Fitness) and hope to be able to report our findings in the near future. In the meantime, it does appear that certain loan agreements were breached and we are now considering our options with regards legal recourse for recovery of some of the funds which had been invested into the 3 businesses together with any associated damages. It was mentioned in the year end report that £513,000 was believed to have been invested in ErgoDynamics Participations BV; this has since proved to have been untrue but as at the date of this report, these funds have still not been adequately accounted for.

Emotion Fitness, our gymnasium business in Hungary, is growing strongly and we intend to continue supporting and developing this operation as we believe there is substantial upside in the wellness and fitness markets in Eastern EuropeDespite a small loss for the 6 month period, we are pleased to report that Emotion Fitness has now moved into profitability on a monthly basis. We will keep shareholders updated on any further developments with regards to this activity

We now have strong management team, efforts are being made to recover as much liquidity from its investments as possible, and your new board is taking a very active role in building shareholder value. 

Adam Reynolds

Chairman

For further information, please contact:

MeDaVinci plc

Adam Reynolds

Paul Foulger

Tel: 0207 245 1100

Zeus Capital Limited

Tel: 0161 831 1512

Ross Andrews

CONSOLIDATED INCOME STATEMENT

FOR THE 6 MONTHS ENDED 30 SEPTEMBER 2009

 

 

Notes

Unaudited6 monthsended 30September2009

Unaudited

 6 months ended 30September2008

Audited

Year

 ended 31March

 2009

£'000

£'000

£'000

Group revenue

-

-

-

Cost of sales

-

-

-

Gross profit

-

-

-

Recurring administrative expenses

(56)

(117)

(307)

Impairment of investments

-

-

(3,430)

Impairment of receivables

-

-

(1,611)

Administrative expenses

(56)

(117)

(5,348)

Finance income:

- bank interest

-

8

10

- interest on loan to associates

-

56

150

- foreign exchange gains

-

-

150

Finance expense:

- change in fair value of derivatives

-

-

(95)

 

Share of post tax loss of associates 

(12)

-

(74)

Loss before taxation

(68)

(53)

(5,207)

Income tax expense

-

-

-

Loss for the period

(68)

(53)

(5,207)

Earnings per share

Basic and diluted

3

(0.03p)

(0.07p)

(7.1p)

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

FOR THE 6 MONTHS ENDED 30 SEPTEMBER 2009

Unaudited6 months ended 30 September 2009

Unaudited6 months ended 30 September 2008

Audited Year ended 31 March 2009

£'000

£'000

£'000

Loss for the period

(68)

(53)

(5,207)

Other comprehensive income

Net exchange differences on translating foreign operations

-

143

118

Total comprehensive income for the period

(68)

90

(5,089)

 

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT 30 SEPTEMBER 2009

Notes

Unaudited

as at 30September2009

Unaudited

as at 30September2008

Audited

as at 31

 March

 2009

£'000

£'000

£'000

Assets

Non-current assets

Property, plant and equipment

-

7

-

Investments in associates

5

338

3,429

350

Available for sale financial assets

-

40

-

Loans to associates

411

1,637

411

Derivative financial instruments-Conversion rights

29

509

29

778

5,622

790

Current assets

Trade and other receivables

-

120

14

Cash and cash equivalents

389

220

117

389

340

131

Current liabilities

Trade and other payables

(139)

(99)

(247)

Current tax payable

-

(10)

-

Net current assets

250

231

(116)

Total assets less current liabilities

1,028

5,853

674

Equity

Share capital

1,158

736

736

Other reserves

5,536

5,561

5,536

Retained earnings

(5,666)

(444)

(5,598)

Total equity

1,028

5,853

674

The financial statements were approved by the Board of Directors on 18 December 2009.

Paul Foulger

Director

CONSOLIDATED CASH FLOW STATEMENT

FOR THE 6 MONTHS ENDED 30 SEPTEMBER 2009

Notes

Unaudited6 months ended 30September2009

Unaudited

6 months ended 30September2008

Auditedyear

 to 31March 2009

£'000

£'000

£'000

Cash flow from operating activities

Cash generated from operations

4

(150)

(110)

(110)

Interest received

-

8

10

Net cash flow from operating activities

(150)

(102)

(100)

Cash flows from investing activities

Acquisition of investments

-

-

-

Purchase of property, plant and equipment

-

-

-

Increase in loans to associates

-

(408)

(513)

Net cash flow from investing activities

-

(408)

(513)

Cash flows from financing activities

Proceeds from issue of equity instruments

422

-

-

Net cash flow from financing activities

422

-

-

Net decrease in cash and cash equivalents

272

(510)

(613)

Cash and cash equivalents at beginning of the period

117

730

730

Cash and cash equivalents at end of the period

389

220

117

 

STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY

FOR THE 6 MONTHS ENDED 30 SEPTEMBER 2009

Share

Capital

Share premium

Retained earnings

Foreign currency reserve

Associates fair value reserve

Total

£'000

£'000

£'000

£'000

£'000

£'000

For the period ended 30 September 2009

At 1 April 2009

736

5,305

(5,598)

712

(481)

674

Loss for the period attributable to equity shareholders

-

-

(68)

-

-

(68)

Unrealised exchange movement

-

-

-

-

-

-

Movement in period

-

-

(68)

-

-

(68)

At 30 September 2009

736

5,305

(5,666)

712

(481)

606

Share

Capital

Share premium

Retained earnings

Foreign currency reserve

Associates fair value reserve

Total

£'000

£'000

£'000

£'000

£'000

£'000

For the period ended 30 September 2008

At 1 April 2008

736

5,305

(391)

594

(481)

5,763

Loss for the period attributable to equity shareholders

-

-

(53)

-

-

(53)

Unrealised exchange movement

-

-

-

143

-

143

Movement in period

-

-

(53)

143

-

90

At 30 September 2008

736

5,305

(444)

737

(481)

5,853

Share

Capital

Share premium

Retained earnings

Foreign currency reserve

Associates fair value reserve

Total

£'000

£'000

£'000

£'000

£'000

£'000

For the year ended 31 March 2009

At 1 April 2008

736

5,305

(391)

594

(481)

5,763

Loss for the year attributable to equity shareholders

-

-

(5,207)

-

-

(5,207)

Unrealised exchange movement

-

-

-

118

-

118

Movement in year

-

-

(5,207)

118

-

(5,089)

At 31 March 2009

736

5,305

(5,598)

712

(481)

674

 

NOTES TO THE INTERIM UNAUDITED FINANCIAL INFORMATION

1. General Information

MeDaVinci plc is a public limited company governed by UK Law, established in the UK and listed on the Alternative Investment Market (AIM). The company's registered office is in the UK. Its office address is 14 Kinnerton Place SouthLondon SW1X 8EH.

The principal activity of the Group is to invest in health and wellness based companies.

The comparative figures included in this report for the six months ended 30 September 2008 are unaudited. The twelve months to 31 March 2009 are audited.

The financial information in this statement does not constitute statutory accounts under Section 434 of the Companies Act and was not subject to a formal review by the auditors. The financial information in respect of the year ended 31 March 2009 has been extracted from the statutory accounts which have been filed with the Registrar of Companies and which included a qualified audit report arising from a limitation of scope on the additional investments in associates during that year.

 

These consolidated interim financial information have been prepared in accordance with International Financial Reporting Standards ("IFRS") as adopted by the European Union, using the accounting policies which are consistent with those set out in the Company's Annual Report and Accounts for the year ended 31 March 2009. This interim financial information for the six months to 30 September 2009, which complies with IAS 34 'Interim Financial Reporting', was approved by the Board on 18 December 2009.

 

2. Significant Accounting Policies

Except as described below, the accounting policies applied are consistent with those of the annual financial statements for the year ended 31 March 2009, as described in those annual financial statements.

Taxes on income in the interim periods are accrued using the tax rate that would be applicable to expected total annual earnings.

The following new standards and amendments to standards are mandatory for the first time for the financial year beginning 1 April 2009.

IAS 1 (revised), 'Presentation of financial statements'. The revised standard prohibits the presentation of items of income and expenses (that is 'non-owner changes in equity') in the statement of changes in equity, requiring 'non-owner changes in equity' to be presented separately from owner changes in equity. All 'non-owner changes in equity' are required to be shown in a performance statement.

Entities can choose whether to present one performance statement (the statement of comprehensive income) or two statements (the income statement and statement of comprehensive income).

The group has elected to present two statements: an income statement and a statement of comprehensive income. The interim financial statements have been prepared under the revised disclosure requirements.

The following new standards, amendments to standards and interpretations have been issued, but are not effective for the financial year beginning 1 April 2009 and have not been early adopted:

IFRS 3 (revised), 'Business combinations' and consequential amendments to IAS 27, 'Consolidated and separate financial statements', IAS 28, 'Investments in associates' and IAS 31, 'Interests in joint ventures', effective prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after 1 July 2009. Management is assessing the impact of the new requirements regarding acquisition accounting, consolidation and associates on the group. 

The revised standard continues to apply the acquisition method to business combinations, with some significant changes. For example, all payments to purchase a business are to be recorded at fair value at the acquisition date, with contingent payments classified as debt subsequently re-measured through the statement of comprehensive income. There is a choice on an acquisition-by-acquisition basis to measure the minority interest in the acquiree either at fair value or at the minority interest's proportionate share of the acquiree's net assets. All acquisition-related costs should be expensed. The group will apply IFRS 3 (revised) to all business combinations from 1 April 2010.

IFRIC 17, 'Distributions of non-cash assets to owners', effective for annual periods beginning on or after 1 July 2009. This is not currently applicable to the group, as it has not made any non-cash distributions.

IFRIC 18, 'Transfers of assets from customers', effective for transfers of assets received on or after 1 July 2009. This is not relevant to the group, as it has not received any assets from customers.

The following new standards, amendments to standards and interpretations are mandatory for the first time for the financial year beginning 1 April 2009, but are not currently relevant for the group

IFRS 8, 'Operating segments'

 

IFRS 2 (amendment), 'Share-based payment'
IAS 23 (amendment), 'Borrowing costs'.
IAS 32 (amendment), 'Financial instruments: Presentation'.
IFRIC 13, 'Customer loyalty programmes'.
IFRIC 15, 'Agreements for the construction o f real estate'.
IFRIC 16, 'Hedges of a net investment in a foreign operation'.
IAS 39 (amendment), 'Financial instruments: Recognition and measurement'.

3. Earnings per share

Basic

Basic earnings per share is calculated by dividing the profit attributable to equity shareholders by the weighted average number of ordinary shares in issue during the period.

Unaudited

6 months ended 30 September

2009

Unaudited

6 months ended 30 September

2008

Audited

year

ended 31 March

2009

£'000

£'000

£'000

Loss attributable to equity holders of the company

(68)

(53)

(5,207)

Weighted average number of ordinary shares in issue (thousands)

267,094

73,600

73,600

Basic earnings per share (pence)

(0.03)

(0.07)

(7.1)

4. Cash Flow from Operating Activities

Unaudited

6 months ended 30 September

2009

Unaudited

6 months ended 30 September

2008

Audited

year

ended 31 March

2009

£'000

£'000

£'000

Loss before taxation

(68)

(53)

(5,207)

Depreciation

-

1

-

Finance income

-

(64)

(310)

Finance expense

-

-

95

Share of loss in investments in associates

12

-

74

Impairment loss on investments and loans

-

-

5,041

Changes in working capital (excluding effect of acquisitions and disposals)

(56)

(116)

(307)

Decrease in trade and other receivables

14

42

93

(Decrease)/increase in trade and other payables

(108)

(36)

104

Cash outflow from operations

(150)

(110)

(110)

5. Investments in Associates

At 30 September

2009

At 30 September 2008

At 31 March

 2009

£'000

£'000

£'000

At fair value

At beginning of period

350

3,306

3,306

Additions

-

123

-

Share in the result

(12)

-

(74)

Impairment during the year

-

-

(2,882)

At end of period

338

3,429

350

6. Called Up Share Capital

At 30 September

2009

At 30 September 2008

At 31 March2009

Numbers

('000)

Numbers

('000)

Numbers

('000)

Authorised

Ordinary shares of 1 pence each

-

500,000

500,000

Ordinary shares of 0.1 pence each

4,337,602

-

-

Deferred shares of 0.9 pence each

73,600

4,411,202

500,000

500,000

Issued

Ordinary shares of 1 pence each

-

73,600

73,600

Ordinary shares of 0.1 pence each

495,140

-

-

Deferred shares of 0.9 pence each

73,600

At end of period

568,740

73,600

73,600

On 26 May 2009 the nominal value of each share was reduced from 1 pence to 0.1 pence and each authorised but unissued Ordinary share of 1 pence was subdivided into 10 Ordinary shares of 0.1 pence. Following this, the Group's issued Ordinary Share capital comprised 73,600,000 Ordinary shares of nominal value 0.1 pence each and 73,600,000 deferred shares of 0.9 pence each.

On 8 July 2009 the company issued 421,540,000 shares of 0.1 pence each. The total cash consideration received amounted to £421,540.

7. A copy of this announcement is available form the Company's web site, being www.medavinciplc.com

ENDS

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR UWAKRKRRUARA
Date   Source Headline
11th Jun 20261:07 pmRNSTransaction in Own Shares and Total Voting Rights
3rd Jun 20263:36 pmRNSNotification of major holdings
1st Jun 20263:40 pmRNSTransaction in Own Shares and Total Voting Rights
11th May 20263:27 pmRNSNotification of major holdings
5th May 20268:17 amRNSHolding(s) in Company
1st May 202611:48 amRNSHolding(s) in Company
30th Apr 20261:41 pmRNSTransaction in Own Shares and Total Voting Rights
23rd Apr 20269:25 amRNSHolding(s) in Company
21st Apr 20264:30 pmRNSHolding(s) in Company
14th Apr 20267:00 amRNSFull Year Trading Update
1st Apr 202610:31 amRNSResult of General Meeting
25th Mar 202612:00 pmRNSTransaction in Own Shares and Total Voting Rights
13th Mar 20267:00 amRNSNotice of General Meeting
13th Mar 20267:00 amRNSNotice of General Meeting
3rd Mar 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
20th Feb 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
13th Feb 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
6th Feb 20261:47 pmRNSTransaction in Own Shares and Total Voting Rights
2nd Feb 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
29th Jan 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
20th Jan 20262:00 pmRNSTransaction in Own Shares and Total Voting Rights
20th Jan 20267:00 amRNSBoard Change
19th Jan 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
16th Jan 20262:10 pmRNSNotification of major holdings
15th Jan 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
13th Jan 20267:00 amRNSTrading Update
6th Jan 202612:00 pmRNSTransaction in Own Shares and Total Voting Rights
2nd Jan 20267:00 amRNSHolding(s) in Company
2nd Jan 20267:00 amRNSHolding(s) in Company
18th Dec 20252:24 pmRNSTransaction in Own Shares and Total Voting Rights
18th Dec 20252:24 pmRNSTransaction in Own Shares and Total Voting Rights
18th Dec 20257:00 amRNSRestructuring of executive share incentives
12th Dec 20254:49 pmRNSNotification of major holdings
26th Nov 20253:08 pmRNSNotification of major holdings
25th Nov 20257:00 amRNSHalf Year Results
21st Nov 202511:42 amRNSNotification of major holdings
20th Nov 20257:00 amRNSNotification of major holdings
13th Nov 20257:00 amRNSNotification of major holdings
10th Nov 20254:33 pmRNSNotification of Major Holdings
29th Oct 20257:00 amRNSNotice of Results and Investor Presentation
20th Oct 202510:18 amRNSDirector/PDMR Shareholding
20th Oct 20257:00 amRNSTransaction in Own Shares
16th Oct 20252:03 pmRNSHolding(s) in Company
16th Oct 202511:24 amRNSCapital Reduction - Effective
14th Oct 20254:00 pmRNSCapital Reduction - Court Approval
14th Oct 20257:00 amRNSHalf Year Trading Update
3rd Oct 202512:32 pmRNSHolding(s) in Company
2nd Oct 20255:22 pmRNSHolding(s) in Company
24th Sep 20252:56 pmRNSNotification of major holdings
23rd Sep 20255:35 pmRNSNotification of major holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.